Patients often avoid the chemotherapy recommended for aggressive, but possibly curable, non-Hodgkin's lymphoma because of severe side effects, thereby hurting their chances of a successful outcome, a study reveals. One of the major side effects that prompted the dose reduction was a drop in the number of white blood cells, which leaves cancer patients open to infections.

Full Story:
USA Today

Related Summaries